UK Indefinitely Bans Puberty Blockers for Minors Citing Unacceptable Safety Risks
In a significant policy shift, the United Kingdom government has enacted an indefinite ban on the use of puberty blockers for individuals under 18 years old diagnosed with gender dysphoria. This decision, announced in December 2024, follows expert advice from the independent Commission on Human Medicines (CHM), which identified an “unacceptable safety risk” associated with their continued use in this age group within the current prescribing environment. The regulations formalize and extend temporary measures implemented in May 2024, responding to concerns raised by the interim and final reports of the Cass Review into gender identity services for children and young people [gov.uk](https://www.gov.uk/government/news/ban-on-puberty-blockers-to-be-made-indefinite-on-experts-advice).
The indefinite ban means that puberty-suppressing hormones, also known as gonadotrophin-releasing hormone (GnRH) analogues, can no longer be privately prescribed for gender dysphoria in minors in the UK. This also applies to prescriptions issued by prescribers registered in the European Economic Area or Switzerland for any reason to those under 18. The legislation, effective January 1, 2025, will undergo its first review in 2027 [bmj.com](https://www.bmj.com/content/387/bmj.q2814.full.pdf).
Rationale Behind the Ban
The primary driver for this indefinite prohibition stems from a comprehensive evaluation by the CHM, which concluded that there is insufficient evidence to support the long-term safety and efficacy of puberty blockers for gender incongruence in young people. Health and Social Care Secretary Wes Streeting emphasized that “children’s healthcare must always be evidence-led,” highlighting concerns about medications prescribed to vulnerable children without proven safety or effectiveness through rigorous clinical trials [gov.uk](https://www.gov.uk/government/speeches/health-and-social-care-secretarys-statement-puberty-blockers).
The ban builds upon recommendations from the Cass Review, led by Dr. Hilary Cass, former president of the Royal College of Paediatrics and Child Health. Her review consistently highlighted a lack of robust evidence concerning the impact of puberty blockers on gender dysphoria, mental health, and long-term psychosocial outcomes. The National Institute for Health and Care Excellence (NICE) had previously conducted an evidence-based review in 2020, and updated in 2023, finding that puberty blockers had no statistically significant impact on gender incongruence, mental health, body image, or psychosocial functioning in children and adolescents, noting the low quality of available evidence [gov.uk](https://www.gov.uk/government/consultations/proposed-changes-to-the-availability-of-puberty-blockers-for-under-18s/proposed-changes-to-the-availability-of-puberty-blockers).
Dr. Cass stated that puberty blockers are “powerful drugs with unproven benefits and significant risks,” and her review recommended that their use should be confined to a research protocol following a multi-disciplinary assessment [gov.uk](https://www.gov.uk/government/news/ban-on-puberty-blockers-to-be-made-indefinite-on-experts-advice).
Impact on Current and Future Patients
The indefinite ban affects new patients under 18 seeking puberty blockers for gender incongruence. However, NHS patients already receiving these medications for gender incongruence will continue to have access. Similarly, individuals receiving these medicines for other medical conditions, such as precocious puberty, are not impacted by the ban [gov.uk](https://www.gov.uk/government/news/ban-on-puberty-blockers-to-be-made-indefinite-on-experts-advice).
For young people whose access to puberty-suppressing hormones may be discontinued, NHS England is offering targeted support from local mental health services. This initiative aims to address the potential mental health and well-being challenges that may arise from the restrictions. Affected individuals and their families can contact [email protected] or call 0300 131 6775 to access this support. Additionally, the NHS website provides advice on obtaining urgent mental health support [gov.uk](https://www.gov.uk/government/consultations/proposed-changes-to-the-availability-of-puberty-blockers-for-under-18s/proposed-changes-to-the-availability-of-puberty-blockers).
Future Directions and Clinical Trials
Acknowledging the existing evidence gaps, the UK government is prioritizing the development of a robust evidence base for puberty blockers. The National Institute for Health and Care Research (NIHR) is collaborating with NHS England to establish a clinical trial for puberty-suppressing hormones. This trial, intended to be the first of its kind globally, aims to recruit its first patients by spring 2025. The goal is to gain a clearer understanding of the effects of these hormones on young people and provide the comprehensive evidence needed for future policy decisions [gov.uk](https://www.gov.uk/government/speeches/health-and-social-care-secretarys-statement-puberty-blockers).
Alongside the ban, NHS England is implementing reforms to gender identity services, establishing new regional centers across the country. These centers will offer a “fundamentally different clinical model” focusing on holistic support, integrating expertise from pediatrics, neurodiversity, and mental health. Three new regional centers are already operational in London, the North West, and Bristol, with a fourth expected to open in the East of England in early 2025. The aim is to have specialist gender services for children and young people in all seven NHS regions by 2026 to 2027 [gov.uk](https://www.gov.uk/government/news/ban-on-puberty-blockers-to-be-made-indefinite-on-experts-advice).
This policy change reflects a precautionary approach in pediatric care, prioritizing patient safety and evidence-based medicine, and underscores the ongoing global debate on gender-affirming care for minors. Read more on Globally Pulse about gender-affirming care guidelines worldwide.
